bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
#asco22 #plenary dr. yoshino presents "panitumumab (pan)+ mfolfox6 versus bevacizumab (bev)+ mfolfox6 in 1st-line left-sided raswt #crcsm: paradigm trial! mos: 37.9 mos vs 34.3 for left-sided mos: 36.2 vs 31.3 for overall
rr/r0 resection rates 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own